Abstract 225P
Background
Common evolution of non-muscle invasive bladder cancer (NMIBC) is local recurrence or progression to muscle invasive bladder cancer (MIBC). Some patients (pts) with NMIBC might develop metastases without progression to MIBC. Clinical evolution of these atypical presentations is unknown. Bladder cancer over the last 5 years has surged by over 13% in India. 50-70% of NMIBC cases recur, and around 10-20% progress to MIBC. Challenge in treatment is identifying the patients with mutations or gene expression patterns for targeted therapy, which is not feasible for all owing to high cost. While omics categorized Western patients, molecular landscape of Indian NMIBC remains incomplete. Herein we report a potential predictive signature, derived by combining transcriptome and whole exome sequencing data of a cohort of NMIBC patients treated in our centre.
Methods
From 2018 to 2021, 25 pts treated at our centre were included for the study, which has been approved by Institutional Ethics committee. Median age at diagnosis was 64Y. 88% received intravesical BCG. 60% were T1 stage and recurrence rate 48%. RNA sequencing and whole exome sequencing were performed on 25 primary NMBIC tumors. Machine learning model was used to predict recurrence status. Mutational status between recurrent and non-recurrent patients was also obtained. The gene expression signature was validated in external datasets including GSE13507 and GSE154261.
Results
435 genes were differentially expressed between recurred and non-recurred patients (p<0.05). Machine learning model predicted recurrence with 90% accuracy. Top pathways upregulated include signalling by nuclear receptors, Shigellosis etc. Downregulated include cell adhesion, PIK-AKT, and ECM reorganization. Validation in external dataset correlated positively with p<0.05. In addition to most previously reported signatures and APOBEC, we also found mutations in FGFR3, ABC transporters, and DAMP, differentially regulated between recurred vs non recurred patients.
Conclusions
We identified novel differentially regulated genes and mutations in genes that predicts recurrence with 90% accuracy. Further analysis in a larger set is underway to complete the validation of the predictive model.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sri Shankara Cancer Hospital and Research Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
362P - Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC)
Presenter: Irene Braña
Session: Poster Display
Resources:
Abstract
363P - Effect of financial distress and mental well-being of patients with early vs advanced oral cancer on informal caregiver's quality of life: A prospective real-world data from public health sector hospital
Presenter: Abhinav Thaduri
Session: Poster Display
Resources:
Abstract
364P - Artificial intelligence provides more accurately neck lymph nodes auto-segmentation in radiotherapy
Presenter: chiencheh Chen
Session: Poster Display
Resources:
Abstract
365P - Radiotherapy treatment outcomes and treatment compliance of nasopharyngeal cancer patients in Sabah: A retrospective analysis
Presenter: Anbarasan Anbazagan
Session: Poster Display
Resources:
Abstract
366P - Pre-treatment oral fungal microbiome and nasopharyngeal carcinoma prognosis: A population-based cohort study in southern China
Presenter: Yufeng Chen
Session: Poster Display
Resources:
Abstract
367P - Prevalence and association of sarcopenia with mortality in patients with head and neck cancer: A meta-analysis
Presenter: Claire Lim
Session: Poster Display
Resources:
Abstract
368P - Distinct gene expression profiling explored using nanostring tumor signalling 360 panel with validations in different clinical stages of oral submucous fibrosis patients: A first Indian study
Presenter: Yasasve Madhavan
Session: Poster Display
Resources:
Abstract
370P - Low-dose nivolumab with induction chemotherapy for inoperable HNSCC in 111 patients: Response rates, survival, and implications for LMICs
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
371P - The role of FDG-PET/CT in the assessment of response to radiation therapy in head and neck cancers: A systematic review and meta-analysis
Presenter: Felix Wijovi
Session: Poster Display
Resources:
Abstract
372P - Effectiveness of HAN-MI-RADS (head and neck molecular imaging-reporting and data system) criterion in head and neck squamous cell carcinoma post concurrent chemoradiotherapy
Presenter: Manoj Gupta
Session: Poster Display
Resources:
Abstract